Adenoviral vaccination combined with CD40 stimulation and CTLA-4 blockage can lead to complete tumor regression in a murine melanoma model (Q56798203)

4

0 references

Allan Randrup Thomsen

object named as

Allan R. Thomsen

Allan R Thomsen

5

0 references

Peter Johannes Holst

2

object named as

Peter J Holst

0 references

author name string

Maria R. Sorensen

1

0 references

Maria A. Steffensen

3

0 references

Maria R Sorensen

1

0 references

Maria A Steffensen

3

0 references

Jan P Christensen

Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice

4

0 references

language of work or name

English

0 references

publication date

September 2010

0 references

24 September 2010

0 references

number of pages

8

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

0 references

volume

28

0 references

issue

41

0 references

page(s)

6757-6764

0 references

6757-64

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.066

Virus-based immunotherapy of cancer: what do we know and where are we going?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.066

CD40 AND CD154 IN CELL-MEDIATED IMMUNITY

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.066

Help for cytotoxic-T-cell responses is mediated by CD40 signalling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.066

CD40/CD154 interactions at the interface of tolerance and immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.066

A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.066

Delivery of antigen to CD40 induces protective immune responses against tumors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.066

Killing of normal melanocytes, combined with heat shock protein 70 and CD40L expression, cures large established melanomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.066

Intratumoral administration of immature dendritic cells following the adenovirus vector encoding CD40 ligand elicits significant regression of established myeloma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.066

Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.066

The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.066

Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.066

Cytotoxic T-lymphocyte-associated antigen-4.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.066

CD4+ regulatory T cells require CTLA-4 for the maintenance of systemic tolerance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.066

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.066

The effect of a therapeutic dendritic cell-based cancer vaccination depends on the blockage of CTLA-4 signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.066

Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accomp

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.066

CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.066

Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.066

The clinical utility of cytotoxic T lymphocyte antigen 4 abrogation by human antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.066

Treatment of transplanted CT26 tumour with dendritic cell vaccine in combination with blockade of vascular endothelial growth factor receptor 2 and CTLA-4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.066

MHC Class II-Associated Invariant Chain Linkage of Antigen Dramatically Improves Cell-Mediated Immunity Induced by Adenovirus Vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.066

Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4+T-cell-independent CD8+T-cell-mediated tumor control

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.066

Use of recombinant adenovirus for metabolic engineering of mammalian cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.066

The SCID but not the RAG-2 gene product is required for S mu-S epsilon heavy chain class switching.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.066

Deficient CD4+ T cell priming and regression of CD8+ T cell functionality in virus-infected mice lacking a normal B cell compartment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.066

Longevity of Antigen Presentation and Activation Status of APC Are Decisive Factors in the Balance Between CTL Immunity Versus Tolerance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.066

Suppression of mature dendritic cell function by regulatory T cells in vivo is abrogated by CD40 licensing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.066

Adenovirus-induced maturation of dendritic cells through a PI3 kinase-mediated TNF-alpha induction pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.066

Role of MyD88 and TLR9 in the innate immune response elicited by serotype 5 adenoviral vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.066

Multiple CD4 and CD8 T-cell activation parameters predict vaccine efficacy in vivo mediated by individual DC-activating agonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.066

Enhanced efficacy and reduced toxicity of multifactorial adjuvants compared with unitary adjuvants as cancer vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.066

Optimising anti-tumour CD8 T-cell responses using combinations of immunomodulatory antibodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.066

Cancer despite immunosurveillance: immunoselection and immunosubversion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.066

CD8+ T-cell memory in tumor immunology and immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.066

Redefining chronic viral infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.066

Manipulating both the inhibitory and stimulatory immune system towards the success of therapeutic vaccination against chronic viral infections.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.066

Molecular signature of CD8+ T cell exhaustion during chronic viral infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.066

Twelve immunotherapy drugs that could cure cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.066